Xiaomeng Li1, Li Sun1, Xue Wang1, Nan Wang1, Kanghong Xu1, Xinquan Jiang1, Shuo Xu2,3. 1. School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, China. 2. Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China. 3. Brain Science Research Institute, Shandong University, Jinan, China.
Abstract
Background: A variety of regulatory approaches including immune modulation have been explored as approaches to either eradicate antitumor response or induce suppressive mechanism in the glioblastoma microenvironment. Thus, the study of immune-related long noncoding RNA (lncRNA) signature is of great value in the diagnosis, treatment, and prognosis of glioblastoma. Methods: Glioblastoma samples with lncRNA sequencing and corresponding clinical data were acquired from the Cancer Genome Atlas (TCGA) database. Immune-lncRNAs co-expression networks were built to identify immune-related lncRNAs via Pearson correlation. Based on the median risk score acquired in the training set, we divided the samples into high- and low-risk groups and demonstrate the survival prediction ability of the immune-related lncRNA signature. Both principal component analysis (PCA) and gene set enrichment analysis (GSEA) were used for immune state analysis. Results: A cohort of 151 glioblastoma samples and 730 immune-related genes were acquired in this study. A five immune-related lncRNA signature (AC046143.1, AC021054.1, AC080112.1, MIR222HG, and PRKCQ-AS1) was identified. Compared with patients in the high-risk group, patients in the low-risk group showed a longer overall survival (OS) in the training, validation, and entire TCGA set (p = 1.931e-05, p = 1.706e-02, and p = 3.397e-06, respectively). Additionally, the survival prediction ability of this lncRNA signature was independent of known clinical factors and molecular features. The area under the ROC curve (AUC) and stratified analyses were further performed to verify its optimal survival predictive potency. Of note, the high-and low-risk groups exhibited significantly distinct immune state according to the PCA and GSEA analyses. Conclusions: Our study proposes that a five immune-related lncRNA signature can be utilized as a latent indicator of prognosis and potential therapeutic approach for glioblastoma.
Background: A variety of regulatory approaches including immune modulation have been explored as approaches to either eradicate antitumor response or induce suppressive mechanism in the glioblastoma microenvironment. Thus, the study of immune-related long noncoding RNA (lncRNA) signature is of great value in the diagnosis, treatment, and prognosis of glioblastoma. Methods:Glioblastoma samples with lncRNA sequencing and corresponding clinical data were acquired from the Cancer Genome Atlas (TCGA) database. Immune-lncRNAs co-expression networks were built to identify immune-related lncRNAs via Pearson correlation. Based on the median risk score acquired in the training set, we divided the samples into high- and low-risk groups and demonstrate the survival prediction ability of the immune-related lncRNA signature. Both principal component analysis (PCA) and gene set enrichment analysis (GSEA) were used for immune state analysis. Results: A cohort of 151 glioblastoma samples and 730 immune-related genes were acquired in this study. A five immune-related lncRNA signature (AC046143.1, AC021054.1, AC080112.1, MIR222HG, and PRKCQ-AS1) was identified. Compared with patients in the high-risk group, patients in the low-risk group showed a longer overall survival (OS) in the training, validation, and entire TCGA set (p = 1.931e-05, p = 1.706e-02, and p = 3.397e-06, respectively). Additionally, the survival prediction ability of this lncRNA signature was independent of known clinical factors and molecular features. The area under the ROC curve (AUC) and stratified analyses were further performed to verify its optimal survival predictive potency. Of note, the high-and low-risk groups exhibited significantly distinct immune state according to the PCA and GSEA analyses. Conclusions: Our study proposes that a five immune-related lncRNA signature can be utilized as a latent indicator of prognosis and potential therapeutic approach for glioblastoma.
Authors: Dass S Vinay; Elizabeth P Ryan; Graham Pawelec; Wamidh H Talib; John Stagg; Eyad Elkord; Terry Lichtor; William K Decker; Richard L Whelan; H M C Shantha Kumara; Emanuela Signori; Kanya Honoki; Alexandros G Georgakilas; Amr Amin; William G Helferich; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Alan Bilsland; Dipita Bhakta; Dorota Halicka; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Beom K Choi; Byoung S Kwon Journal: Semin Cancer Biol Date: 2015-03-25 Impact factor: 15.707
Authors: Yuanliang Yan; Zhijie Xu; Xi Chen; Xiang Wang; Shuangshuang Zeng; Zijin Zhao; Long Qian; Zhi Li; Jie Wei; Lei Huo; Xuejun Li; Zhicheng Gong; Lunquan Sun Journal: Front Cell Dev Biol Date: 2019-10-02
Authors: Yalan Lei; Rong Tang; Jin Xu; Bo Zhang; Jiang Liu; Chen Liang; Qingcai Meng; Jie Hua; Xianjun Yu; Wei Wang; Si Shi Journal: Bioengineered Date: 2021-12 Impact factor: 3.269